HTG MOLECULAR DIAGNOSTICS IN - COM (HTGM)

CUSIP: 40434H104

Q4 2018 13F Holders as of 31 Dec 2018

Type / Class
Equity / COM
Total 13F shares
14,564,952
Share change
+1,107,641
Total reported value
$36,985,000
Price per share
$2.54
Number of holders
48
Value change
-$2,751,738
Number of buys
25
Number of sells
27

Quarterly Holders Quick Answers

What is CUSIP 40434H104?
CUSIP 40434H104 identifies HTGM - HTG MOLECULAR DIAGNOSTICS IN - COM in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Institutional Holders of HTG MOLECULAR DIAGNOSTICS IN - COM (HTGM) as of Q4 2018

As of 31 Dec 2018, HTG MOLECULAR DIAGNOSTICS IN - COM (HTGM) was held by 48 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 14,564,952 shares. The largest 10 holders included FMR LLC, Stonepine Capital Management, LLC, PRICE T ROWE ASSOCIATES INC /MD/, Vanguard Group Inc, PUTNAM INVESTMENTS LLC, GRANAHAN INVESTMENT MANAGEMENT INC/MA, Alyeska Investment Group, L.P., PERKINS CAPITAL MANAGEMENT INC, National Asset Management, Inc., and ACADIAN ASSET MANAGEMENT LLC. This page lists 48 institutional shareholders reporting positions in this security for the Q4 2018 filing period.
Investor Option Weight % Change % Value $ * Price Shares Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.